尤瑞克林联合奥扎格雷钠治疗急性脑梗死的疗效观察

Curative effect of urinary kallidinogenase combined with ozagrel sodium on acute cerebral infarction

目的探讨尤瑞克林联合奥扎格雷钠治疗急性脑梗死的临床疗效。方法将170例急性脑梗死患者随机分为对照组和治疗组,各85例,对照组给予奥扎格雷钠治疗,治疗组给予尤瑞克林联合奥扎格雷钠治疗。观察两组患者临床疗效、美国国立卫生研究院卒中量表评分(HINSS)、梗死体积、血液流变学指标及不良反应情况。结果两组患者性别、年龄、伴发病及病发部位等一般资料无显著性差异(P>0.05),具有可比性。治疗组疗效显著优于对照组(Z=-2.28,P=0.02);NIHSS评分方面,对照组治疗前后分别为23.38±3.24 vs 12.22±7.17,治疗组为23.18±2.96 vs 9.16±6.95,治疗组治疗后效果优于对照组(t=2.83,P<0.05);梗死体积方面,对照组治疗前后分别为5.99±0.60 vs 5.00±0.34,治疗组为5.99±0.62 vs 4.00±0.21,治疗组治疗后效果优于对照组(t=23.11,P<0.05);血液流变学各项指标,治疗组纤维蛋白原、血浆黏度、全血低切黏度和全血高切黏度改善程度均优于对照组(t值分别为14.67,7.35,19.70和5.33,P<0.05);两组不良反应发生情况无明显差异。结论尤瑞克林联合奥扎格雷钠可有效治疗急性脑梗死,在扩血管、抗凝的基础上修复受损神经元,改善患者预后,且无明显严重不良反应,值得临床推广。

Objective To evaluate the clinical efficacy of urinary kallidinogenase combined with sodium ozagrel on acute cerebral infarction. Methods Totally 170 cases of acute cerebral infarction were randomly and equally divided into control group and treatment group. The control group was treated with ozagrel sodium while the treatment group was given urinary kallidinogenase combined with ozagrel sodium. The clinical efficacy,HINSS score,infarct volume,blood rheology and adverse reactions of the two groups were observed. Results There was no significant difference in such general data as gender,age,site of disease and complications between the two groups（ P〉0. 05）. The efficacy of the treatment group was significantly better than that of the control group（ Z =-2. 28,P = 0. 02）. The NIHSS score before and after treatment was（ 23. 38 ± 3. 24） vs（ 12. 22 ± 7. 17） respectively in the control group,and（ 23. 18 ± 2. 96） vs（ 9. 16 ± 6. 95） in the treatment group. The effect in the treatment group was better than in the control group（ t = 2. 83,P〈0. 05）. The infarct volume before and after treatment was（ 5. 99 ± 0. 60） vs（ 5. 00 ± 0. 34） respectively in control group,and（ 5. 99 ＋ 0. 62） vs（ 4. 00 ± 0. 21）in the treatment group. The effect in the treatment group was better than in the control group（ t = 23. 11,P〈0. 05）. Blood rheology indexes,fibrinogen,plasma viscosity,whole blood low shear viscosity and whole blood viscosity improvement in the treatment group were better than those in the control group（ t = 14. 67,7. 35,19. 70 和 5. 33,P〈0. 05）. The two groups were not significantly different in the incidence of adverse reactions. Conclusion Yuri Klein combined with ozagrel sodium can effectively treat acute cerebral infarction by repairing the damaged neurons and improving the prognosis of patients,without obvious adverse reactions. It is worthy of clinical promotion.